170 related articles for article (PubMed ID: 34799485)
21. KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma.
Choi SM; Andea AA; Wang M; Behdad A; Shao L; Zhang Y; Lu X; Dittmann D; Castro J; Chen YH; Gao J
Diagn Pathol; 2018 Oct; 13(1):78. PubMed ID: 30322385
[TBL] [Abstract][Full Text] [Related]
22. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.
Hartmann S; Döring C; Vucic E; Chan FC; Ennishi D; Tousseyn T; de Wolf-Peeters C; Perner S; Wlodarska I; Steidl C; Gascoyne RD; Hansmann ML
Br J Haematol; 2015 May; 169(3):415-22. PubMed ID: 25644177
[TBL] [Abstract][Full Text] [Related]
23. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
24. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
25. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
[No Abstract] [Full Text] [Related]
27. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Swerdlow SH
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
[TBL] [Abstract][Full Text] [Related]
29. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.
Wang C; Shi F; Liu Y; Zhang Y; Dong L; Li X; Tong C; Wang Y; Su L; Nie J; Han W
J Hematol Oncol; 2021 Jul; 14(1):106. PubMed ID: 34225766
[TBL] [Abstract][Full Text] [Related]
30. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.
Klapper W; Kreuz M; Kohler CW; Burkhardt B; Szczepanowski M; Salaverria I; Hummel M; Loeffler M; Pellissery S; Woessmann W; Schwänen C; Trümper L; Wessendorf S; Spang R; Hasenclever D; Siebert R;
Blood; 2012 Feb; 119(8):1882-7. PubMed ID: 22238326
[TBL] [Abstract][Full Text] [Related]
31. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
32. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
34. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
[TBL] [Abstract][Full Text] [Related]
35. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
[TBL] [Abstract][Full Text] [Related]
37. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.
Aukema SM; Kreuz M; Kohler CW; Rosolowski M; Hasenclever D; Hummel M; Küppers R; Lenze D; Ott G; Pott C; Richter J; Rosenwald A; Szczepanowski M; Schwaenen C; Stein H; Trautmann H; Wessendorf S; Trümper L; Loeffler M; Spang R; Kluin PM; Klapper W; Siebert R;
Haematologica; 2014 Apr; 99(4):726-35. PubMed ID: 24179151
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
39. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
40. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement.
Barth TF; Müller S; Pawlita M; Siebert R; Rother JU; Mechtersheimer G; Kitinya J; Bentz M; Möller P
J Pathol; 2004 Aug; 203(4):940-5. PubMed ID: 15258997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]